President Donald Trump on Saturday signed an executive order providing up to $50 million for states to begin research on ibogaine, a psychedelic that shows promise of treating opioid use disorder, post-traumatic stress disorder and other maladies.
The new funding comes as states advance their own efforts to conduct clinical trials, allocating millions for studies into an alternative treatment that has never been authorized in the United States.
Already a subscriber? Sign in